LimFlow, Inc. news

Initial findings of an early feasibility trial have demonstrated that the LimFlow System does represent a safe and reproducible method of treating patients with no-option critical limb ischaemia (CLI). The results of PROMISE I, which were described by chief investigator Daniel Clair (University of South Carolina, Columbia, USA) as “very promising”, show the potential of the system for improving wound healing rates and reducing the number of amputations performed.